Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial

Platinum-based combination chemotherapy has been proven to be superior to single-agent platinum in the treatment of relapsed ovarian cancer after a treatment-free interval of more than 6 months. A response rate of 41% was previously reported by our group using a combination of epirubicin, cisplatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothermundt, C, Hubner, R, Ahmad, T, Gibbens, I, Keyzor, C, Habeshaw, T, Kaye, S, Gore, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361084/
https://www.ncbi.nlm.nih.gov/pubmed/16306873
http://dx.doi.org/10.1038/sj.bjc.6602879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361084/
https://www.ncbi.nlm.nih.gov/pubmed/16306873
http://dx.doi.org/10.1038/sj.bjc.6602879

Ejemplares similares